2823-19-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-1-(2-fluorophenyl)-1-oxobutane is used as an active pharmaceutical ingredient for its neuroprotective properties. It is particularly valuable in the development of treatments for various neurological disorders and conditions, such as dyskinesias and psychotic disorders, due to its analog nature to Haloperidol.
Used in Research and Development:
In the field of scientific research, 4-Chloro-1-(2-fluorophenyl)-1-oxobutane is used as a research compound to study its potential effects on the central nervous system. This helps researchers gain a better understanding of its mechanisms of action and how it can be utilized in the development of new drugs and therapies for neurological conditions.
Used in Drug Design and Synthesis:
4-Chloro-1-(2-fluorophenyl)-1-oxobutane is also used as a key intermediate in the synthesis of novel drugs with potential applications in the treatment of various neurological and psychiatric disorders. Its unique chemical structure allows for the development of new molecules with improved efficacy and reduced side effects.
Overall, 4-Chloro-1-(2-fluorophenyl)-1-oxobutane is a versatile compound with significant potential in the pharmaceutical and research industries, particularly in the development of treatments for neurological and psychiatric disorders. Its neuroprotective properties and analog nature to Haloperidol make it a valuable asset in the ongoing quest for more effective and safer therapeutic options.

InChI:InChI=1/C10H10ClFO/c11-7-3-6-10(13)8-4-1-2-5-9(8)12/h1-2,4-5H,3,6-7H2

Upstream product

• 1251109-63-3 1-(4-chlorobut-1-yn-1-yl)-2-fluorobenzene 

Downstream Products

• 1391052-53-1 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(2-fluorophenyl)butan-1-one 
• 1228568-65-7 (R)-2-(2-fluorophenyl)pyrrolidine 

Relevant academic research and scientific papers

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

Synthesis of the ortho / meta / para isomers of relevant pharmaceutical compounds by coupling a Sonogashira reaction with a regioselective hydration

Aryl ketones substituted in ortho, meta, and para position are prepared by a palladium-catalyzed Sonogashira reaction followed by a regioselective hydration of the so-formed alkyne with triflimidic acid or a gold catalyst, under catalytic conditions. This methodology opens a way to obtain substituted aryl alkyl ketones from readily available starting materials, haloarenes, and terminal alkynes. The syntheses of the different regioisomers of haloperidol, melperone, pipamperone, and ibuprofen are presented. Structure-activity relationships for these compounds are studied with dopaminergic and cyclooxigenase binding assays.